PTC Therapeutics, Inc.: 10-Q filed 2016-11-03
What PTC Therapeutics, Inc. reported in its quarterly report filed 2016-11-03 (fiscal Q3 2016): 32 published measures, 88 facts as tagged in accession 0001070081-16-000005.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-11-03
- Fiscal period
- fiscal Q3 2016
- Accession
- 0001070081-16-000005 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PTC Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 288,177,000 | USD | |
| At 2015-12-31 | 365,281,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 148,000,000 | USD | |
| At 2015-12-31 | 139,280,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 140,177,000 | USD | |
| At 2015-12-31 | 226,001,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 50,286,000 | USD | |
| At 2015-12-31 | 58,022,000 | USD | |
| At 2015-09-30 | 140,712,000 | USD | |
| At 2014-12-31 | 49,748,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -35,167,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -115,314,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -43,223,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -119,499,000 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 540,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 1,764,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | -708,313,000 | USD | |
| At 2015-12-31 | -592,998,000 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 184,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 206,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 88,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 233,000 | USD | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 7,059,000 | USD | |
| At 2015-12-31 | 8,974,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 26,610,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 26,130,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -32,064,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -107,066,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -42,232,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -118,929,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 280,607,000 | USD | |
| At 2015-12-31 | 355,949,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 48,926,000 | USD | |
| At 2015-12-31 | 45,386,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 19,238,000 | USD | |
| At 2015-12-31 | 11,940,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 55,050,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 164,580,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 52,008,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 142,961,000 | USD | 273 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 1,300,000 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 23,654,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 72,958,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 21,368,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 56,193,000 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 31,396,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 91,622,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 30,640,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 86,768,000 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 34,165,519 | shares | |
| At 2015-12-31 | 33,916,559 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 847,700,000 | USD | |
| At 2015-12-31 | 820,165,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 756,000 | USD | |
| At 2015-12-31 | -1,200,000 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 756,000 | USD | |
| At 2016-06-30 | 885,000 | USD | |
| At 2015-12-31 | -1,200,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 2,515,000 | USD | |
| At 2015-12-31 | 2,046,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 4,860,000 | USD | |
| At 2015-12-31 | 5,930,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -34,983,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -115,108,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -43,135,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -119,266,000 | USD | 273 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -35,167,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -115,314,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -43,223,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -119,499,000 | USD | 273 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -35,296,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -113,358,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -43,855,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -119,889,000 | USD | 273 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -35,167,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -115,314,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -43,223,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -119,499,000 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 2,477,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 2,079,000 | USD | 273 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -786,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -1,893,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -51,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -507,000 | USD | 273 |
Deferred income tax expense or benefit
The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | -222,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 0 | USD | 273 |
Income taxes paid, net
Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 633,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 0 | USD | 273 |
Inspect the source
- Entity
- PTC Therapeutics, Inc. / CIK 0001070081
- Captured
- 2026-09-20T05:19:30.322Z
- SEC response SHA-256
d748041dc0149cc4539c2407042aaa6286795ec2b9d1722f0cb5484cca6764d4
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001070081.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))